Kazakhstan Pharmaceuticals & Healthcare Q4 2018
Kazakhstan’s pharmaceutical market will experience double-digit growth through to 2022 and will be one of the fastestgrowing markets in the Central and Eastern Europe (CEE) region. The country is attracting greater foreign investment into itsdomestic pharmaceutical industry, with Roche and Servier the latest multinational drugmakers to commit to the market. In Addition,the state-owned SK-Pharmacy new tender favouring domestically-produced medicines in line with international standards will, inour view, lead to further investment in the domestic industry. However, given the government’s plans to expand healthcare accessand Kazakhstan’s low affordability levels, we believe opportunities will remain heavily within the generic medicines sector.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook